SARS-CoV-2 and Guillain-Barré syndrome: AIDP variant with a favourable outcome.
COVID-19
electrodiagnostic testing
immune-mediated disorder
immunoglobulin therapy
infection
polyradiculoneuropathy
Journal
European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311
Informations de publication
Date de publication:
09 2020
09 2020
Historique:
received:
25
04
2020
accepted:
21
05
2020
pubmed:
2
6
2020
medline:
29
12
2020
entrez:
2
6
2020
Statut:
ppublish
Résumé
The spectrum of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2), includes different neurologic manifestations of the central and peripheral nervous system. From March through April 2020, in two university hospitals located in western Switzerland, we examined three patients with Guillain-Barré syndrome (GBS) following SARS-CoV-2. These cases were characterized by a primary demyelinating electrophysiological pattern (Acute inflammatory demyelinating polyneuropathy or AIDP) and a less severe disease course compared to recently published case series. Clinical improvement was observed in all patients at week five. One patient was discharged from hospital after full recovery with persistence of minor neurological signs (areflexia). Two of the three patients remained hospitalized: one was able to walk and the other could stand up with assistance. We report three cases of typical GBS (AIDP) occurring after SARS-CoV-2 infection and presenting with a favourable clinical course. Given the interval between COVID-19-related symptoms and neurological manifestations (mean of 15 days) we postulate a secondary immune-mediated mechanism rather than direct viral damage.
Sections du résumé
BACKGROUND AND PURPOSE
The spectrum of COVID-19, caused by severe acute respiratory syndrome coronavirus 2 infection (SARS-CoV-2), includes different neurologic manifestations of the central and peripheral nervous system.
METHODS
From March through April 2020, in two university hospitals located in western Switzerland, we examined three patients with Guillain-Barré syndrome (GBS) following SARS-CoV-2.
RESULTS
These cases were characterized by a primary demyelinating electrophysiological pattern (Acute inflammatory demyelinating polyneuropathy or AIDP) and a less severe disease course compared to recently published case series. Clinical improvement was observed in all patients at week five. One patient was discharged from hospital after full recovery with persistence of minor neurological signs (areflexia). Two of the three patients remained hospitalized: one was able to walk and the other could stand up with assistance.
CONCLUSIONS
We report three cases of typical GBS (AIDP) occurring after SARS-CoV-2 infection and presenting with a favourable clinical course. Given the interval between COVID-19-related symptoms and neurological manifestations (mean of 15 days) we postulate a secondary immune-mediated mechanism rather than direct viral damage.
Identifiants
pubmed: 32478936
doi: 10.1111/ene.14368
pmc: PMC7300656
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Types de publication
Case Reports
Langues
eng
Sous-ensembles de citation
IM
Pagination
1751-1753Informations de copyright
© 2020 European Academy of Neurology.
Références
Lancet. 2020 Feb 15;395(10223):470-473
pubmed: 31986257
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
N Engl J Med. 2016 Oct 20;375(16):1513-1523
pubmed: 27705091
N Engl J Med. 2020 Jun 4;382(23):2268-2270
pubmed: 32294339
N Engl J Med. 2020 Jun 25;382(26):2574-2576
pubmed: 32302082
Lancet Neurol. 2020 May;19(5):383-384
pubmed: 32246917
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288